Ultra‑Sensitive, Non‑Invasive Surveillance Solution Expected to Launch Commercially in the U.S. in 2027 as Part of CareDx’s Transplant+ Precision Medicine Portfolio BRISBANE, Calif., February 12, 2026 ...

Dr. Mazzone and colleagues report on a cell-free DNA fragmentome assay (DELFIscore) for the classification of lung cancer (1). We have concerns and recommendations. Study participants were enrolled ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...

By utilizing a standardized methodology for evaluating novel digital measures, sDHT developers, biostatisticians and clinical researchers will be able to navigate the complex validation landscape more ...

Abstract: Existing research suggests that lower limb exoskeleton robots, when used for rehabilitation training based on the pre-stroke gait trajectories of stroke patients, may be more beneficial for ...

NEW YORK – Personalized cancer firm Artera this week presented four studies on its multimodal artificial intelligence (MMAI) digital pathology-based risk stratification platform at the annual ...

Health care leaders may want to keep a closer eye on clinical validation for artificial intelligence (AI)-enabled medical devices (AIMDs), based on a recent JAMA Health Forum study. The study examined ...

Copyright: © 2025 The Author(s). Published by Elsevier Ltd.

Artificial intelligence-enabled medical devices with no clinical validation were more likely to be the subject of recalls, according to a study published in JAMA Health Forum. The study, published on ...

Clinical outcomes of patients with stage I triple-negative breast cancer (TNBC) treated with or without chemotherapy: The Mayo Clinic experience. ATX evaluated across 5 cohorts individually and pooled ...

Beta-CORRECT study to be presented at ASCO 2025 confirms the clinical utility of the molecular residual disease (MRD) test, Oncodetect™, for recurrence monitoring in stage II–IV colorectal cancer ...